TCF7L2

Across TCGA pan-cancer cohorts, TCF7L2 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of TCF7L2’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where TCF7L2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types TCF7L2 is over-expressed in tumor, although a few such as LUAD and LSCC show the opposite, repressed pattern.

LUAD, LSCC, and CCRCC are the cancer types where TCF7L2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TCF7L2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Male	II,III,IV	−0.280	.009	3	view →
LSCC	Male	All	−0.333	.009	2	view →
CCRCC	All	All	+0.833	.046	1	view →
PDAC	Female	II,III,IV	+0.316	.043	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

TCF7L2–LUAD

Open the LUAD breakdown →